Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2
=========================================================================================================================================================================

Overexpressions, amplifications and mutations in the tyrosine kinase family\'s *EGFR* and *HER2* genes are thought to play a role in a variety of cancers including breast and gastric cancers. Development of a medication that inhibits both of these two kinases has been ongoing. Currently there are a number of drugs on the market or in the clinical development, but due to limited effectiveness (lapatinib) or higher toxicity profiles (irreversible dual inhibitors), the quest to find a more effective and less harmful dual inhibitor continues. In this study, Tanaka and colleagues investigated a novel reversible dual tyrosine kinase inhibitor, S-222611, and were able to show that S-222611 has both a higher efficacy than lapatinib in a variety of animal models, including in intracranial transplantation model where S-222611 exerted promising activity for brain metastasis. Also S-222611 showed a better safety profile than irreversible inhibitors. This exciting new drug has now proceeded to clinical trials.doi: [10.1111/cas.12449](10.1111/cas.12449)
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*In vivo* imaging of membrane type-1 MMP with a novel activatable near-infrared fluorescence probe
==================================================================================================

Membrane type-1 matrix (MT1) MMP is a protease believed to play an important role in the metastatic potential of cancer cells. One function of MT1-MMP may be in promoting epithelial--mesenchymal transition, a crucial step in malignant progression. There have been limits in the ability of researchers to study MT1-MMP *in vivo*, but here Shimizu *et al*. describe their development of an *in vivo* method for optical imaging of the protease. The authors accomplished this feat using cutting-edge methods combining cell culture and a rodent model. Most impressively, they successfully developed a fluorescence assay to optically detect MT1-MMP in tumors from xenografted mice. This method paves the way for further work in the field to help further elucidate the function and significance of MT1-MMP activity in tumor progression.doi: [10.1111/cas.12457](10.1111/cas.12457)
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Newly defined aberrant crypt foci as a marker for dysplasia in the rat colon
============================================================================

In the evaluation of the carcinogenicity of chemicals, rat colons are often analyzed for markers of dysplastic lesions after exposure to the chemical in question. However, the method by which labeling of these possible dysplastic markers is done remains controversial as it is thought that it might be marking lesions that will never develop into cancer, as well as precancerous lesions. In this original and creative study, Ochiai *et al*. investigated a new method by which to investigate precancerous lesions, in which only the aberrant crypt sections of the colon were stained with azoxymethane and those that demonstrated compressed luminal openings proved (by thin slice section verification) to be highly dysplastic. This quicker method is thus likely to be as effective as the pain-staking process of examining the entire colon, and likely more accurate in the identification of lesions that will indeed become cancer.doi: [10.1111/cas.12446](10.1111/cas.12446)
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